Table 1.

Summarisation of cases

Cases	Case 1	Case 2	Case 3
Age of onset (years)	60	68	62
Gender	Female	Female	Male
Statin	Atorvastatin and rosuvastatin	Atorvastatin	Atorvastatin
Duration from symptom onset to presentation	2 months	1 month	12 months
Duration from commencement of statin to symptom onset	Atorvastatin: few months Rosuvastatin: 2 months	Atorvastatin: 3 years	Atorvastatin: 3 years
Pattern of weakness	Proximal upper and lower limbs	Proximal upper and lower limbs	Proximal, especially hip girdle
Initial peak CK	11 003	3900	5000
Anti-HMGCR antibody at presentation	54.4 RU (normal range <11.0 RU)	49.0 RU (normal range <11.0 RU)	0.84 (normal <0.24 OD units)
Muscle biopsy	Focal segmental necrotising myopathy with minimal inflammation	Moderate necrotising myopathy with minimal inflammation	Necrotising myopathy
Immunotherapies trialled	Prednisolone Methotrexate Cyclosporine IVIG	Prednisolone Methotrexate Cyclosporine IVIG	Prednisolone Methotrexate Cyclosporine IVIG Plasma exchange
Current immunotherapy	Methotrexate Rituximab	Methotrexate IVIG Rituximab	Methotrexate IVIG Rituximab
Current status	Stable CK (<100 U/L) Normal anti-HMGCR antibody level Mild weakness	Stable CK (200~300 U/L) Reduced anti-HMGCR antibody level Mild weakness	Stable CK (100~300 U/L) Anti-HMGCR antibody level still elevated Mild weakness

anti-HMGCR, antibodies to 3-hydroxy-3-methylglutaryl coenzyme A reductase; CK, creatine kinase; IVIG, intravenous immunoglobulin; OD, Optical Density; RU, Reference Unit.